337 related articles for article (PubMed ID: 29722201)
1. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
Nissinen TA; Hentilä J; Penna F; Lampinen A; Lautaoja JH; Fachada V; Holopainen T; Ritvos O; Kivelä R; Hulmi JJ
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):514-529. PubMed ID: 29722201
[TBL] [Abstract][Full Text] [Related]
2. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
[TBL] [Abstract][Full Text] [Related]
3. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.
Lautaoja JH; Lalowski M; Nissinen TA; Hentilä J; Shi Y; Ritvos O; Cheng S; Hulmi JJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E852-E865. PubMed ID: 30860875
[TBL] [Abstract][Full Text] [Related]
4. Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver.
Hentilä J; Nissinen TA; Korkmaz A; Lensu S; Silvennoinen M; Pasternack A; Ritvos O; Atalay M; Hulmi JJ
Front Physiol; 2018; 9():1917. PubMed ID: 30713500
[TBL] [Abstract][Full Text] [Related]
5. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
6. Muscle NAD
Hulmi JJ; Penna F; Pöllänen N; Nissinen TA; Hentilä J; Euro L; Lautaoja JH; Ballarò R; Soliymani R; Baumann M; Ritvos O; Pirinen E; Lalowski M
Mol Metab; 2020 Nov; 41():101046. PubMed ID: 32599075
[TBL] [Abstract][Full Text] [Related]
7. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.
Hulmi JJ; Nissinen TA; Penna F; Bonetto A
Cells; 2021 Feb; 10(3):. PubMed ID: 33671024
[TBL] [Abstract][Full Text] [Related]
9. mTOR and Tumor Cachexia.
Duval AP; Jeanneret C; Santoro T; Dormond O
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061533
[TBL] [Abstract][Full Text] [Related]
10. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
11. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.
Hatakeyama S; Summermatter S; Jourdain M; Melly S; Minetti GC; Lach-Trifilieff E
Skelet Muscle; 2016; 6():26. PubMed ID: 27462398
[TBL] [Abstract][Full Text] [Related]
12. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
[TBL] [Abstract][Full Text] [Related]
13. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
[TBL] [Abstract][Full Text] [Related]
14. Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress.
Hulmi JJ; Hentilä J; DeRuisseau KC; Oliveira BM; Papaioannou KG; Autio R; Kujala UM; Ritvos O; Kainulainen H; Korkmaz A; Atalay M
Free Radic Biol Med; 2016 Oct; 99():308-322. PubMed ID: 27554968
[TBL] [Abstract][Full Text] [Related]
15. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.
Kandarian SC; Nosacka RL; Delitto AE; Judge AR; Judge SM; Ganey JD; Moreira JD; Jackman RW
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1109-1120. PubMed ID: 30270531
[TBL] [Abstract][Full Text] [Related]
16. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
[TBL] [Abstract][Full Text] [Related]
17. Regulation of muscle growth by multiple ligands signaling through activin type II receptors.
Lee SJ; Reed LA; Davies MV; Girgenrath S; Goad ME; Tomkinson KN; Wright JF; Barker C; Ehrmantraut G; Holmstrom J; Trowell B; Gertz B; Jiang MS; Sebald SM; Matzuk M; Li E; Liang LF; Quattlebaum E; Stotish RL; Wolfman NM
Proc Natl Acad Sci U S A; 2005 Dec; 102(50):18117-22. PubMed ID: 16330774
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
20. Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
Talbert EE; Yang J; Mace TA; Farren MR; Farris AB; Young GS; Elnaggar O; Che Z; Timmers CD; Rajasekera P; Maskarinec JM; Bloomston M; Bekaii-Saab T; Guttridge DC; Lesinski GB
Mol Cancer Ther; 2017 Feb; 16(2):344-356. PubMed ID: 27811010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
